Wed, Jul 23, 2014, 11:16 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

TG Therapeutics, Inc. Message Board

jjgiablue 96 posts  |  Last Activity: 2 hours 22 minutes ago Member since: Sep 15, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Gileads black box warning

    by golderw3 4 hours ago
    jjgiablue jjgiablue 2 hours 22 minutes ago Flag

    This from Fiercebiotech: But a black-box warning on the drug's label could stand in its way. Zydelig has been linked to fatal and serious toxicities of the liver, according to the FDA, and its packaging spells out risks of severe diarrhea, colitis, pneumonitis and intestinal perforation. Whether that'll seriously affect its market potential remains to be seen, but investors are taking the warning seriously: Gilead's shares stayed about flat on the announcement, but Pharmacyclics' shot up more than 10% on Wednesday morning.

  • Reply to

    In due time.

    by pharmatheway 12 hours ago
    jjgiablue jjgiablue 6 hours ago Flag

    Within the 1101/1202 results this week was mention of higher response rates for certain indications where 1202 was dosed at the highest dose available in the study. This sort of supports TGTX's effort to modify the 1202 dosage to achieve higher exposure levels. It's still speculative at this point, but this approach could provide a clinical benefit and differentiating benefit relative to other PI3K deltas in terms of exposure levels and clinical efficacy in addition to the already known safety benefit of 1202.

  • Reply to


    by innsbrooklad Jul 22, 2014 5:11 PM
    jjgiablue jjgiablue 7 hours ago Flag

    PBYI ph III data related to HER2+ EARLY stage BC patients. The data looked great, and that's a big patient population. MM398 looks good too but in a smaller patient population - 2nd line PC. MM121 still has promise - i'm waiting for the triple negative BC results. When are those due?

  • Reply to

    In due time.

    by pharmatheway 12 hours ago
    jjgiablue jjgiablue 11 hours ago Flag

    Roth sometimes (and sometimes not) has good analysis on stocks but Brean is consistently pretty solid in analyzing biotech stocks.

  • Reply to

    Stock decline

    by jjgiablue Jul 22, 2014 10:15 AM
    jjgiablue jjgiablue Jul 22, 2014 1:00 PM Flag

    could be - although i think the reaction is stronger than i would have expected.

  • Reply to

    Two upgrades today!

    by golderw3 Jul 22, 2014 7:51 AM
    jjgiablue jjgiablue Jul 22, 2014 12:46 PM Flag

    while i think the data was positive, i think some were expecting even more in terms of efficacy. I don't think the sell off is simply a buy the rumor/sell the news thing - i think it's a fundamental reaction to the data by some fund investors and retail investors.

  • Reply to

    Stock decline

    by jjgiablue Jul 22, 2014 10:15 AM
    jjgiablue jjgiablue Jul 22, 2014 10:17 AM Flag

    Possibly higher expectations for DLBCL - maybe investors view other delta combination with rituxan as just as good

  • jjgiablue by jjgiablue Jul 22, 2014 10:15 AM Flag

    while i thought the data of 1101 and 1202 looked quite positive, the market obviously thinks otherwise. Any thoughts?

  • Reply to

    Stock will be down before days over....

    by johnamkins Jul 22, 2014 9:44 AM
    jjgiablue jjgiablue Jul 22, 2014 10:06 AM Flag

    still don't understand why the stock is down - the data looked good to me

  • Reply to

    Two upgrades today!

    by golderw3 Jul 22, 2014 7:51 AM
    jjgiablue jjgiablue Jul 22, 2014 9:24 AM Flag

    i saw the Roth PT raise. What is the other one?

  • Reply to

    MACK close to a deal on MM-398

    by mymandon Jul 17, 2014 4:04 PM
    jjgiablue jjgiablue Jul 18, 2014 4:20 PM Flag

    i'll believe they are close to a deal when they actually announce a deal

  • jjgiablue by jjgiablue Jul 11, 2014 4:06 PM Flag

    I thought topline results were due in Q2 - isn't that right?

  • Reply to

    Will there be a TGTX buyout?

    by paulpathikal Jun 27, 2014 11:49 AM
    jjgiablue jjgiablue Jun 27, 2014 9:40 PM Flag

    Maybe if the data readouts continue to be as positive as they have been. At the end of the year, after ASH, at earliest, but i honestly hope it doesn't happen until much later because i think this company could have a $2B market cap if the data plays out as i hope.

  • Reply to

    Roth Capitol Gave it a $20.00

    by korthh Jun 26, 2014 6:59 PM
    jjgiablue jjgiablue Jun 26, 2014 11:42 PM Flag

    And that price target should go up significantly as more positive data is released related to 1101 and 1202. If 1202 continues to prove to be as potent as idelalisib BUT with lower adverse events (particularly in terms of liver toxicity and potentially also other AEs such as cholitis). It is possible that 1202 may prove to be even more effective than idelalisib if the new 1202 micronized formulations do in fact lead to greater exposure in patients as TGTX's CEO hopes.

    Here is what one analyst said today about Gilead's Idelalisib (and consider that these arguments could apply equally to 1202): We are raising our long-run idelalisib estimates from $773m in 2019 (vs $1.1bn consensus) to $1.5bn in 2019. We now assume $1.2bn for use in CLL /iNHL and a heavily risk-adjusted $300m (20% probability of success) for its possible use in immuno-oncology (I/O) drug combinations that target solid tumours, given the highly promising pre-clinical data showing the pivotal role that idelalisib's target PI3Kδ plays in't reg cell suppression of the anti-cancer effect of CD8+ T-cells.

  • Reply to

    Up to $10.15 After Hours

    by korthh Jun 25, 2014 7:05 PM
    jjgiablue jjgiablue Jun 25, 2014 7:34 PM Flag

    Or maybe just TGTX's famous volatility - you never know. Anyway - the $10.15 AH trade was just 325 shares. I expect TGTX to be all over the map, up and down, until the next data release in mid July.

  • Reply to

    Every ... single . . . article

    by canphan7 Jun 24, 2014 9:25 PM
    jjgiablue jjgiablue Jun 25, 2014 12:52 AM Flag

    i've noticed that motley fool has tried to be provocative in their titling, not just for MACK but for many other companies, and i think they do this to increase clicks and readers. They are useless, less so than Seeking Alpha (which depending on the SA author is saying something) and should be on everyone's ignore list.

  • Reply to

    JMP Conference Tomorrow

    by korthh Jun 23, 2014 10:21 AM
    jjgiablue jjgiablue Jun 24, 2014 9:10 PM Flag

    It was an interesting call. The stock was all over the place today - but i think that had to the announced in licensing of the Ligand IRAK4 program, but that is so early stage (lead development, they are close to but don't yet have a clinical candidate identified) that it's not likely to yield any data for at least a year and a half.

  • Reply to

    Investor cc

    by lagafroig Jun 24, 2014 4:50 PM
    jjgiablue jjgiablue Jun 24, 2014 8:05 PM Flag

    rumor has it that the official response will be "Sh!t happens"

  • Reply to

    Boogins and Innsbrooklad

    by uvainvestor82 Jun 23, 2014 11:54 PM
    jjgiablue jjgiablue Jun 24, 2014 12:34 AM Flag

    are you the same dbag who chides me on my investment in TGTX? C'mon on over there and change your focus from here. I have even more shares in TGTX.

  • Reply to

    Big Pharma

    by boogins_00 Jun 23, 2014 8:45 AM
    jjgiablue jjgiablue Jun 23, 2014 8:59 PM Flag

    Just to clarify, the reason that Tarceva was returned to OSI was not because Pfizer did not want to develop the drug, it was because Pfizer was in the process of merging with Warner Lambert which had a competing EGFR inhibitor in development. Due to potential FTC concerns, Pfizer parted with the drug that was easiest and quickest to dispose of under the circumstances, and that was Tarceva due to the pre-existing relationship with OSI. Recall that OSI's stock tripled the day it was announced that they were getting full rights to Tarceva from Pfizer. I think the situation here is quite different - in this case, Sanofi has several expensive development programs (I have noted PCSK9) and likely simply decided to drop MM-121 due to resource constraints even though it likely still sees promise in MM-121. There are other examples that are even better than the Tarceva example - focusing on PFE, they outlicensed neratinib (now being developed by Puma). PFE, i am sure, knows that neratinib holds promise and will likely become a drug but likely outlicensed it due to resource constraints. All of big pharma takes this approach - limited R & D resources force it.

9.31+1.06(+12.78%)Jul 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.